GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hainan Poly Pharm Co Ltd (SZSE:300630) » Definitions » Beneish M-Score

Hainan Poly Pharm Co (SZSE:300630) Beneish M-Score : -2.33 (As of May. 17, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Hainan Poly Pharm Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.33 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Hainan Poly Pharm Co's Beneish M-Score or its related term are showing as below:

SZSE:300630' s Beneish M-Score Range Over the Past 10 Years
Min: -2.5   Med: -1.72   Max: 4.34
Current: -2.33

During the past 11 years, the highest Beneish M-Score of Hainan Poly Pharm Co was 4.34. The lowest was -2.50. And the median was -1.72.


Hainan Poly Pharm Co Beneish M-Score Historical Data

The historical data trend for Hainan Poly Pharm Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hainan Poly Pharm Co Beneish M-Score Chart

Hainan Poly Pharm Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.43 -1.39 -1.52 -2.02 -2.50

Hainan Poly Pharm Co Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.63 -2.50 -2.34 -2.37 -2.33

Competitive Comparison of Hainan Poly Pharm Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Poly Pharm Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hainan Poly Pharm Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hainan Poly Pharm Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Hainan Poly Pharm Co's Beneish M-Score falls into.



Hainan Poly Pharm Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Hainan Poly Pharm Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0732+0.528 * 1.2178+0.404 * 1.3131+0.892 * 1.0258+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.4365+4.679 * -0.01692-0.327 * 1.0751
=-2.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was ¥1,424 Mil.
Revenue was 518.194 + 460.874 + 373.166 + 435.653 = ¥1,788 Mil.
Gross Profit was 333.636 + 312.434 + 268.504 + 138.919 = ¥1,053 Mil.
Total Current Assets was ¥2,722 Mil.
Total Assets was ¥6,687 Mil.
Property, Plant and Equipment(Net PPE) was ¥3,228 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥418 Mil.
Total Current Liabilities was ¥1,411 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,903 Mil.
Net Income was 134.355 + 131.512 + 138.433 + -34.848 = ¥369 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -43.107 + 44.819 + 28.783 + 452.109 = ¥483 Mil.
Total Receivables was ¥1,293 Mil.
Revenue was 575.088 + 427.678 + 367.926 + 372.186 = ¥1,743 Mil.
Gross Profit was 449.819 + 308.135 + 292.511 + 200.169 = ¥1,251 Mil.
Total Current Assets was ¥2,211 Mil.
Total Assets was ¥5,606 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,924 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥283 Mil.
Total Current Liabilities was ¥1,160 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,424 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1423.888 / 1787.887) / (1293.33 / 1742.878)
=0.796408 / 0.742066
=1.0732

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1250.634 / 1742.878) / (1053.493 / 1787.887)
=0.717568 / 0.589239
=1.2178

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2722.404 + 3228.011) / 6687.316) / (1 - (2211.165 + 2924.354) / 5605.973)
=0.110194 / 0.08392
=1.3131

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1787.887 / 1742.878
=1.0258

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 2924.354)) / (0 / (0 + 3228.011))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(417.56 / 1787.887) / (283.353 / 1742.878)
=0.233549 / 0.162578
=1.4365

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1903.077 + 1411.094) / 6687.316) / ((1424.28 + 1159.819) / 5605.973)
=0.495591 / 0.460955
=1.0751

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(369.452 - 0 - 482.604) / 6687.316
=-0.01692

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Hainan Poly Pharm Co has a M-score of -2.33 suggests that the company is unlikely to be a manipulator.


Hainan Poly Pharm Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Hainan Poly Pharm Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Hainan Poly Pharm Co (SZSE:300630) Business Description

Traded in Other Exchanges
N/A
Address
No.1509 Binsheng Road, 10th Floor, Zhejiang Province, Hangzhou, CHN, 310051
Hainan Poly Pharm Co Ltd is a pharmaceutical manufacturer in China. It manufactures injections, oral solid formulations, dry suspension, and other active pharmaceutical ingredients. The products offered by the company include Azithromycin for Injection, Ganciclovir Sodium for Injection. Octreotide Acetate Injection, Trimebutine Maleate tablets, Desloratadine, Trimebutine Maleate, and GANCICLOVIR among others.

Hainan Poly Pharm Co (SZSE:300630) Headlines

No Headlines